Cypress Capital Group Has $753,000 Holdings in Becton, Dickinson and Company (NYSE:BDX)

Cypress Capital Group lessened its holdings in Becton, Dickinson and Company (NYSE:BDX) by 13.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,318 shares of the medical instruments supplier’s stock after selling 515 shares during the period. Cypress Capital Group’s holdings in Becton, Dickinson and Company were worth $753,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Tompkins Financial Corp raised its holdings in shares of Becton, Dickinson and Company by 44.2% in the 3rd quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock worth $36,000 after acquiring an additional 46 shares during the last quarter. Radnor Capital Management LLC increased its stake in Becton, Dickinson and Company by 1.7% in the 3rd quarter. Radnor Capital Management LLC now owns 2,937 shares of the medical instruments supplier’s stock valued at $708,000 after buying an additional 48 shares during the last quarter. Wesbanco Bank Inc. increased its stake in Becton, Dickinson and Company by 1.9% in the 4th quarter. Wesbanco Bank Inc. now owns 2,558 shares of the medical instruments supplier’s stock valued at $580,000 after buying an additional 48 shares during the last quarter. Umpqua Bank increased its stake in Becton, Dickinson and Company by 1.8% in the 3rd quarter. Umpqua Bank now owns 2,738 shares of the medical instruments supplier’s stock valued at $660,000 after buying an additional 49 shares during the last quarter. Finally, S.A. Mason LLC increased its stake in Becton, Dickinson and Company by 3.7% in the 4th quarter. S.A. Mason LLC now owns 1,414 shares of the medical instruments supplier’s stock valued at $321,000 after buying an additional 50 shares during the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Trading Down 0.0 %

Shares of BDX stock opened at $224.17 on Thursday. The company has a 50 day moving average of $233.02 and a 200-day moving average of $232.83. The company has a quick ratio of 0.63, a current ratio of 1.13 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a 12-month low of $218.75 and a 12-month high of $251.99. The firm has a market cap of $64.37 billion, a P/E ratio of 37.24, a PEG ratio of 1.63 and a beta of 0.40.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. Sell-side analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company declared that its Board of Directors has approved a stock buyback plan on Tuesday, January 28th that permits the company to repurchase 10,000,000 shares. This repurchase authorization permits the medical instruments supplier to repurchase shares of its stock through open market purchases. Shares repurchase plans are often an indication that the company’s board of directors believes its shares are undervalued.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Investors of record on Monday, March 10th will be issued a $1.04 dividend. This represents a $4.16 annualized dividend and a yield of 1.86%. The ex-dividend date is Monday, March 10th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 69.10%.

Insider Buying and Selling

In related news, EVP Michael David Garrison sold 2,838 shares of the firm’s stock in a transaction that occurred on Thursday, December 19th. The shares were sold at an average price of $223.33, for a total value of $633,810.54. Following the completion of the transaction, the executive vice president now directly owns 6,141 shares of the company’s stock, valued at approximately $1,371,469.53. This trade represents a 31.61 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Roland Goette sold 638 shares of the firm’s stock in a transaction on Monday, December 9th. The shares were sold at an average price of $219.03, for a total transaction of $139,741.14. Following the completion of the transaction, the executive vice president now directly owns 14,217 shares of the company’s stock, valued at approximately $3,113,949.51. The trade was a 4.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 10,544 shares of company stock valued at $2,370,309. Company insiders own 0.36% of the company’s stock.

Wall Street Analysts Forecast Growth

BDX has been the subject of several analyst reports. Barclays increased their price objective on shares of Becton, Dickinson and Company from $278.00 to $279.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. Piper Sandler increased their price objective on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a research note on Tuesday, January 28th. Finally, StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Wednesday. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Becton, Dickinson and Company has an average rating of “Buy” and an average target price of $278.29.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.